Medicine and Health

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

R. R. G. Machado, J. L. Walker, et al.

This study reveals the impressive neutralizing antibody responses and efficacy against the BA.5 challenge in male Syrian hamsters following vaccination with Ad26.COV2.S or BNT162b2, showcasing that a single high dose of Ad26.COV2.S outperforms two doses of BNT162b2. The NVX-CoV2373 booster emerged as the champion in providing robust immunity. Conducted by renowned authors from the University of Texas Medical Branch, this research highlights the potential of various vaccine regimens in combatting BA.5 infection.

00:00

Playback language: English

Index

Abstract

This study evaluates neutralizing antibody responses and efficacy against BA.5 challenge in male Syrian hamsters after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by homologous or heterologous boosters. One high or low dose of Ad26.COV2.S provided more durable immunity than two doses of BNT162b2, and the NVX-CoV2373 booster provided the strongest immunity and protection against BA.5 infection. The data demonstrate the immunogenicity and efficacy of different prime/boost regimens against BA.5.

Publisher

Nature Communications

Published On

Jul 17, 2023

Authors

Rafael R. G. Machado, Jordyn L. Walker, Dionna Scharton, Grace H. Rafael, Brooke M. Mitchell, Rachel A. Reyna, William M. de Souza, Jianying Liu, David H. Walker, Jessica A. Plante, Kenneth S. Plante, Scott C. Weaver

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters

S. Sharma, T. Vercruysse, et al.

Medicine and Health

An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters

S. Deng, Y. Liu, et al.

Medicine and Health

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J. Logue, R. M. Johnson, et al.

Medicine and Health

Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)

A. J. M. Aabakke, T. G. Petersen, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny